ASX:NEU Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis → The Most Dangerous Time for 401k Owners (From Birch Gold) (Ad) Free NEU Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,935 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Neuren Pharmaceuticals alerts: Email Address Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Neuren Pharmaceuticals Stock (ASX:NEU)Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.Read More Ad HedgeyeNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!TRY "INVESTING IDEAS" TODAY NEU Stock News HeadlinesMay 29, 2024 | msn.comThese ASX shares could rise 25% to 35%May 29, 2024 | fool.com.auWhy Cettire, Neuren, Peter Warren, and Qantas shares are falling todayMay 28, 2024 | afr.comASX climbs; Cettire, Lendlease shares jumpMay 28, 2024 | msn.comASX200 rises in strong rebound on May 27 trading dayMay 28, 2024 | msn.comAs it happened: ASX up 0.8pc with solid gains across the board to finish just shy of a record closeMay 28, 2024 | finance.yahoo.comNeuren Pharmaceuticals’ NNZ-2591 shows promise in trial for Pitt Hopkins syndromeMay 27, 2024 | fool.com.auThis ASX 200 stock can rocket to a record high: BrokerMay 27, 2024 | markets.businessinsider.comNeuren's NNZ-259 Phase 2 Trial Demonstrates Significant Improvements In Pitt Hopkins SyndromeMay 23, 2024 | msn.comASX 200 healthcare stock up 40% in 6 months halted ahead of major trial resultsMay 9, 2024 | msn.comWhy this high-flying ASX 200 healthcare stock just crashed 11%April 3, 2024 | msn.comASX loses 1.3% on back of Wall Street decline, gold price hits new high and the world's richest people are getting richer — as it happenedApril 1, 2024 | finance.yahoo.comHere's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of InvestorsMarch 26, 2024 | uk.finance.yahoo.com20 Biggest Health Care Companies in Australia, 2024March 18, 2024 | fool.com.auThe best ASX shares to invest $500 in right nowMarch 11, 2024 | fool.com.au$10k of savings? I'd buy these ASX 200 shares to grow my moneyMarch 3, 2024 | finance.yahoo.comNeuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their ModelsFebruary 29, 2024 | fool.com.auWhat's with the Neuren Pharmaceuticals share price today?February 28, 2024 | msn.comInflation remains at two-year low, Optus sacks extra 200 staff, Sony terminates 8pc of workforce, ASX finishes flat — as it happenedFebruary 28, 2024 | fool.com.auWhy is this ASX 200 pharmaceuticals stock crashing 15% today?February 16, 2024 | msn.comNeuren (NEU) Shares Plunge as Short Seller Targets Partner AcadiaFebruary 15, 2024 | fool.com.auThis ASX 200 healthcare share is diving 13% as short sellers take aimJanuary 18, 2024 | forbes.comStock Market Outlook In 2024January 15, 2024 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Clinuvel Pharmaceuticals Limited (CLVLF)January 12, 2024 | fool.com.au3 pharma shares outshining the ASX index todayJanuary 8, 2024 | fool.com.auThe Neuren Pharmaceuticals share price is up 100% in 3 months: Can it keep rising?See More Headlines Receive NEU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2019Today6/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:NEU CUSIPN/A CIKN/A Webwww.neurenpharma.com Phone61 3 9092 0480FaxN/AEmployees2,105Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$1.20 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$157.08 million Net Margins67.72% Pretax MarginN/A Return on Equity127.30% Return on Assets85.52% Debt Debt-to-Equity RatioN/A Current Ratio5.78 Quick Ratio31.54 Sales & Book Value Annual Sales$231.94 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.46 Book ValueA$1.61 per share Price / BookN/AMiscellaneous Outstanding Shares129,950,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.01 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Jonathan Charles Pilcher A.C.A.ACA, B.Sc., BSc (Hons), F.C.A., CEO, MD & Executive DirectorMs. Lauren Frazer C.A.CFO & Company SecretaryMr. Lawrence Glass BA (Biology)Chief Science OfficerMr. Gerry ZhaoVice President of Corporate DevelopmentDr. Liza A. Squires M.D.Chief Medical OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersJoseph(Joe) BasileBought 5,000 shares on 9/13/2023Total: $59,950.00 ($11.99/share)Trevor ScottSold 1,175,000 sharesTotal: $15.28 M ($13.00/share) NEU Stock Analysis - Frequently Asked Questions How were Neuren Pharmaceuticals' earnings last quarter? Neuren Pharmaceuticals Limited (ASX:NEU) posted its quarterly earnings results on Wednesday, February, 27th. The company reported $0.03 EPS for the quarter. Neuren Pharmaceuticals had a net margin of 67.72% and a trailing twelve-month return on equity of 127.30%. What other stocks do shareholders of Neuren Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuren Pharmaceuticals investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Afterpay (APT) and Alkane Resources (ALK). This page (ASX:NEU) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuren Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.